Phase 3 Study of Navitoclax in Myelofibrosis
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
Disease Types: Hematology
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
For more information:
https://clinicaltrials.gov/ct2/show/NCT04472598?term=TRANSFORM-1&draw=2&rank=1